Oncolytics Biotech Inc. (ONCY) Stock Price & Analysis
Oncolytics Biotech Inc. (ONCY) — MoonshotScore 30/100 (Weak band), calculated Nov 18, 2026. Price $0.3906 (-11.29%), as of the Nov 19, 2026 trading session; market cap $53.2M.
Educational signal · not a buy or sell recommendation · How to read this
Oncolytics Biotech Inc. · ONCY · NASDAQ
Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on the discovery and development of cancer treatments. Their lead product, pelareorep, is an intravenously delivered immunotherapeutic agent targeting solid tumors and hematological malignancies.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Oncolytics Biotech (ONCY)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, a fragile balance sheet, weak growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Slipping.
Free cash flow yield is the main valuation drag relative to sector peers.
- EPS beat 5 of the last 8 reports
Holding back: balance-sheet strain, a rich price, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 30 | Weak | |
| 33 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 30 | Weak | |
| 30 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.3906 | |
| Change on the day | -11.29% | |
| Market capitalisation | $53.2M | — |
| Price / earnings (trailing) | -2.38 | |
| Shares traded on the day | 1.70M |
Price & events
Other perspectives
Council score for Oncolytics Biotech (ONCY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 13, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Oct 13, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Oct 13, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Oncolytics Biotech (ONCY), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Oncolytics Biotech Inc. (ONCY) is listed on NASDAQ. It employs 29 people. The market values it at $53.2M.
What do the latest results show for Oncolytics Biotech (ONCY)?
Short answer · as of
Against analyst estimates the company has EPS beat 5 of the last 8 reports.
What are the financial strengths and risks for Oncolytics Biotech (ONCY)?
Short answer · as of
What is holding it back is balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 0.89 · earnings yield -79.4% · free-cash-flow yield -78.3%.
Data-derived red flags
- Listing risk — at $0.3906 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Oncolytics Biotech (ONCY)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.19M · EPS -0.36 · 4 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for ONCY.
Checked against the records this page reads, on the dates shown above.
How does Oncolytics Biotech compare with its peers?
Short answer
Oncolytics Biotech's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $137.78 Nov 18, 2026 | $340B | 69 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $28.06 Nov 18, 2026 | $160B | 67 5-pillar Nov 18, 2026 | |
| Oncolytics Biotech (ONCY) — this page | $0.3906 | $53.2M | 30 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $1.19M
- EPS estimate
- $-0.36
Measured against a quoted price of $0.3906 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ONCY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ONCY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Oncolytics Biotech (ONCY)?
- Oncolytics Biotech, Coherus Sign Clinical Supply Agreement for Pelareorep Study
- Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma
- Oncolytics Biotech Publishes Data On Pelareorep Immunotherapy In Proceedings Of The National Academy Of Sciences
Oncolytics Biotech Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ONCY research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ONCY?
ONCY carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on the discovery and development of cancer treatments.
Is ONCY a good stock to buy?
Stock Expert AI does not rate ONCY buy, sell or hold. Oncolytics Biotech Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ONCY stock price today?
The last price recorded for Oncolytics Biotech Inc. (ONCY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ONCY?
The main risks for Oncolytics Biotech Inc. (ONCY) are inherent to its development-stage status and the biotechnology industry. Clinical trial failures or negative data readouts pose a significant risk, as they could halt the development of pelareorep and negatively impact the company's valuation.
What are the key factors to evaluate for ONCY?
Oncolytics Biotech Inc. (ONCY) holds a MoonshotScore in the low range. Co-development agreements with Merck KGaA and Pfizer Inc. validate the technology and provide financial support. Not financial advice.
How frequently does ONCY data refresh on this page?
ONCY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ONCY's recent stock price performance?
Oncolytics Biotech Inc. (ONCY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel immunotherapeutic approach with pelareorep. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ONCY overvalued or undervalued right now?
Oncolytics Biotech Inc. (ONCY) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ONCY?
Fractional-share availability for Oncolytics Biotech Inc. (ONCY) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 6 from Financial Modeling Prep (FMP), 7 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com